Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Virology

• Publication date

  1995-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/jvi.69.6.3510-3516.1995PMID 7745698PMCID PMC189064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.

  1995cited by this paper
• Viral dynamics in human immunodeficiency virus type 1 infection

  1995cited by this paper
• Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine

  1995cited by this paper
• Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

  1994cited by this paper
• Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection

  1994cited by this paper
• A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.

  1994cited by this paper
• Quantitation of human immunodeficiency virus plasma RNA by branched DNA and reverse transcription coupled polymerase chain reaction assay methods: A critical evaluation of accuracy and reproducibility

  1994cited by this paper
• Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

  1994cited by this paper
• Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

  1994cited by this paper
• Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.

  1994cited by this paper
• Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group

  1994cited by this paper
• Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

  1994cited by this paper
• Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors

  1993cited by this paper
• Direct and quantitative detection of HIV‐1 RNA in human plasma with a branched DNA signal amplification assay

  1993cited by this paper
• Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.

  1993cited by this paper
• Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

  1993cited by this paper
• Clinical correlates of in vitro HIV‐1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial

  1993cited by this paper
• High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

  1993cited by this paper
• Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection

  1993cited by this paper
• Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells.

  1993cited by this paper
• The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

  1993cited by this paper
• A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.

  1993cited by this paper
• Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

  1993cited by this paper
• A microtitre format point mutation assay: Application to the detection of drug resistance in human immunodeficiency virus type‐1 infected patients treated with zidovudine

  1992cited by this paper
• A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

  1992cited by this paper
• Loss of Synergistic Response to Combinations Containing AZT in AZT-Resistant HIV-1

  1992cited by this paper
• Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

  1992cited by this paper
• Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

  1992cited by this paper
• In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine

  1992cited by this paper
• Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation Group.

  1992cited by this paper
• Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

  1992cited by this paper
• Survival of Zidovudine-Treated Patients With AIDS Compared With That of Contemporary Untreated Patients

  1992cited by this paper
• Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

  1991cited by this paper
• Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis

  1991cited by this paper
• Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

  1991cited by this paper
• Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

  1991cited by this paper
• Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

  1991cited by this paper
• Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

  1990cited by this paper
• Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection

  1990cited by this paper
• 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.

  1990cited by this paper
• Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

  1990cited by this paper
• HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

  1989cited by this paper
• Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

  1989cited by this paper
• Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.

  1989cited by this paper

• The Reverse Transcriptase 67N 70R 215Y Genotype Is the Predominant TAM Pathway Associated with Virologic Failure among HIV Type 1C-Infected Adults Treated with ZDV/ddI-Containing HAART in Southern Africa

  2007cites this paper
• Antiretroviral (ARV) drug resistance in the developing world.

  2007cites this paper
• Demonstration of de Novo HIV Type 1 Production by Detection of Multiply Spliced and Unspliced HIV Type 1 RNA in Paraffin-Embedded Tonsils

  2002cites this paper
• Fluorescence Detection of Specific RNA Sequences Using 2'-Pyrene-Modified Oligoribonucleotides We are very grateful to Professor Hiroshi Sugiyama, Dr. Tetsuji Yamaoka, and Dr. Takashi Morii for ion-spray mass spectrometric measurements and helpful comments on this research.

  2001cites this paper
• In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.

  2001cites this paper
• Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.

  2000cites this paper
• Considerations in the Management of HIV Infection in Patients Undergoing Antineoplastic Chemotherapy

  2000cites this paper
• Mutational Patterns in the HIV Genome and Cross-Resistance following Nucleoside and Nucleotide Analogue Drug Exposure

  2000cites this paper
• Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine

  1999cites this paper
• Statistical and econometric analysis of the treatment of HIV/AIDS

  1999cites this paper
• Managing Resistance to Anti-HIV Drugs

  1999cites this paper
• Decreased Processivity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Containing Didanosine-Selected Mutation Leu74Val: a Comparative Analysis of RT Variants Leu74Val and Lamivudine-Selected Met184Val

  1999cites this paper
• Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

  1999cites this paper
• Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy

  1998cites this paper
• Saquinavir delays the emergence of zidovudine resistance in HIV‐1 seropositive patients treated with combination therapy

  1998cites this paper
• Report of the NIH Panel To Define Principles of Therapy of HIV Infection*

  1998cites this paper
• Inhibition of Friend virus replication by a compound that reacts with the nucleocapsid zinc finger: anti-retroviral effect demonstrated in vivo.

  1998cites this paper
• The clinical utility of viral quantitation using molecular methods.

  1998cites this paper
• Antiviral Activities of 9-R-2-Phosphonomethoxypropyl Adenine (PMPA) and Bis(isopropyloxymethylcarbonyl)PMPA against Various Drug-Resistant Human Immunodeficiency Virus Strains

  1998influential citation
• Optimization of Specimen-Handling Procedures for Accurate Quantitation of Levels of Human Immunodeficiency Virus RNA in Plasma by Reverse Transcriptase PCR

  1998cites this paper
• Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy

  1998cites this paper
• Cutting out the middleman: DNA biosensors based on electrochemical oxidation

  1998cites this paper
• Méthodes d'analyse de la sensibilité des virus aux antiviraux : tests phénotypiques et génotypiques

  1998cites this paper
• Estado actual de la evaluación y manejo del paciente HIV positivo con métodos de laboratorio

  1998cites this paper
• Probing biomolecule recognition with electron transfer: electrochemical sensors for DNA hybridization.

  1997cites this paper
• Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.

  1997cites this paper
• The application of the polymerase chain reaction to the study of human immunodeficiency virus type 1 infection

  1997cites this paper
• Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation

  1997cites this paper
• Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years

  1997cites this paper
• Application of an expert system in the management of HIV-infected patients.

  1997cites this paper
• Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.

  1996cites this paper
• Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo

  1996cites this paper
• Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication

  1996cites this paper
• Use of Quantitative Molecular Methods in Studying Human Immunodeficiency Virus Type 1 Infection

  1996cites this paper
• Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection

  1996cites this paper
• Dried blood spots collected on filter paper: an international resource for the diagnosis and genetic characterization of human immunodeficiency virus type-1.

  1996cites this paper
• The Effects of Antineoplastic Chemotherapy on HIV Disease

  1996cites this paper
• Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatment

  1996cites this paper
• Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients

  1996cites this paper
• HIV viral load markers in clinical practice

  1996cites this paper
• Perspective: research highlights of the University of Alabama at Birmingham Center for AIDS Research. Paradigm shifts, translational research, and CFARs.

  1996cites this paper
• Effect of antiretroviral therapy on plasma HIV RNA.

  1995cites this paper
• Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance

  1995cites this paper
• and M zidovudine resistance . human immunodeficiency virus type 1 determination of relative amounts of genotypic Nonisotopic hybridization assay for

  1995cites this paper
• FORM A . Report Title : Report of the NIH PANEL TO Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-lnfected Adults and Adolescents

  year unknowncites this paper